Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (September 2012)
35 slides from Fluoropharma Medical's investor presentation, Sep 11, 2012
Slide 1: Enabling Personalized Medicine by Making the Invisible, Visible
F Luau. 2 Pharma Enabling Personalized Medicine by Making the Invisible, Visible.
Slide 2: Forward-Looking Statements
Fluoro Forward-Looking Statements. Pharma This presentation contains “forwarclooking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. which are intended to be covered b
Slide 3: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance ‘THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS PATIENT MANAGEMENT + Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital + Next generation molecular imaging drugs for diagnostic testing +
Slide 4: Investment Highlights
Fluoro Investment Highlights harma Proprietary products that support new technologies for personalized medicine + Next generation /firstin-class diagnostic imaging + Helps determine the course of cardiac treatment Two Phase ILready products with short study timelines, both directed to very large mar
Slide 5: The Next Big Step in Healthcare
The Next Big Step in Healthcare MEDICINE TODAY One treatment fits all - => still a guessing game B www. FluoroPharma.com
Slide 6: Personalized Diagnosis
Personalized Diagnosi: MEDICINE TOMORROW must be personalized Right Treatment for the Right Patient at the Right Time for the Right Outcome y Before you can see it, Before the patient feels it, We can identify it Personalized medicine begins with the right diagnosis www. FluoroPharma.com
Slide 7: Unmet Need for Better Imaging Methods
met Need for Better Imaging Methods harma MRI FDA Warning in 2007 + Nephrogenic systemic fibrosis for Gadolinium-based contrastagents 7 =m ANATOMICAL »> Fa . FDA Warning in 2007 IMAGING Coes - Diya (| eae ‘AHA 2007 Statement + CTAis reasonable forassessment of CAD in symptomatic patients + Not recom
Slide 8: Large, Growing Market for Imaging Agents
Large, Growing Market for Imaging Agents harma + Global market projected to exceed $15 billion by 2015 + Fueled by need for personalized medicine + Additional drivers include: + Growing volume of diagnostic examinations and equipment sales + Advanced imaging agents in development *+ Aging population
Slide 9: PET Imaging Roots are in Oncology
PET Imaging Roots are in Oncology harma PET procedures by disease area 2500 g 20 3 2 Cardiology Faces and 5 neurology H remain & 1000 strong growth ‘5 opportunities 500 ° 2008 2005 2006 2007 2008 sor Year I Oncology Ml Neurology lll Cardiology www. FluoroPharma.com ‘Source: Fron & Saven 2008
Slide 10: Cardiovascular Disease is the Next Big Opportunity
Cardiovascular Disease is the Next Big Opportunity Zz Phar ‘ma Total diagnostic radiopharmaceutical agents market: Cardiac imaging procedures are the greatest opportunity to switch to PET Procedures 25) (milions) sey 304 | CAGR 07-09 PET (Total) 17.0% SPECT (Cardiac) 7.39% ‘SPECT (Other) 5.3% Total
Slide 11: FluoroPharma Enables Personalized Diagnosis
FluoroPharma Enables Personalized Diagnosis harma Imaging provides non-invasive tools with immediate personalized recommendations for treatment Spatial Temporal atrast Resolution Resolution Resolutio Method direct visual evaluation of + Measures the efficacy of treatment <2mm - Single bi Optical Tia
Slide 12: Poised to Capture Cardio Diagnostics
Poised to Capture Cardio Diagnostics harma Cardiovascular Diagnostics PET Molecular Imaging + Lin adults have some form of CV + Superior image quality disease + PETisa large and rapidly growing + $403 billion: fully burdened cost of imaging platform cAD + Increasing demand for PET + ~ 12 milion CV n
Slide 13: Making the Invisible, Visible
Fluoro Making the Invisible, Visible harma BFPET CardioPET VasoPET Formeasuring ardiovascular blood flow + For use in combination with (MFA) ss-testingin patients with deisgned to optimize imagi cells and rapidly dividing cells presumptive chronic CAD * Diagnosis of acute and chron + No uptake in st
Slide 14: Robust Portfolio On-Track
Robust Portfolio On-Track ‘saucer compte aise erin Fuacfome reach eres: Pc mean Une Deseret ies ‘GrevexPangrestconire Pon acs 1805008 NON xa Bethe 5 Spent 230 fp pe eres comenere ors meres Memes charg wh Bes MHP, www. FluoroPharma.com DRAFT
Slide 15: Product Portfolio Market Size and Revenue Opportunity
Product Portfolio Market Size and Revenue Opportunity BFPET CardioPET VasoPET 12.0m azam 555m 30-50% 30-50% 15% 3.66.0m 528.7m 0.9m FPMIPET 40.90% 21-41% 100% Marke 145.4m 133.6m 0.9m FPMI Procedures $600 $600 $600 $0.93.28 $0.8228 $510M aan, Sacer ae Raeta age ee EN RO Ear OORT ‘www.FluoroPharma.co
Slide 16: BFPET Clinical Use
ET Clinical Use harma MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD + Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress CURRENT DIAGNOSTIC TEST *+ Perfusion imaging with SPECT tracers (e.g. MIBI, tetrophosmin, 11-201) or Rb-82 CLINICAL
Slide 17: BFPET Phase I Trial Findings
BFPET Phase | Trial Findings harma mpleted + Rapid extraction from blood + Stable heart uptake over time + High target to background rati + No clinically significant changes noted Si abet ec (aes in follow-up clinical and laborator ¢ Convenientimegng window rene ai y + Whole body effective dose: 73.
Slide 18: The BFPET Opportunity
The BFPET Opportunity. harma Projected BFPET Scans umptions iLLions 14 Est. 5! Year Revenue 42 $691 million Est. PET “0 st Market Patient me auents MarketSize os Myocardial 06 Perfusion 12 milion 3.6 milion imaging 04 02 00 Yeart Year3 Years www. FluoroPharma.com
Slide 19: CardioPET Clinical Use
CardioPET Clinical Use harma CARDIAC VIABILITY ASSESSMENT * Identify patients that may benefit from PCI or revascularization and guide intervention + Evaluate CAD in patients that cannot exercise CURRENT TREATMENT + Invasive coronary angiography CLINICAL NEED + 1.3 million diagnostic angiography pro
Slide 20: CardioPET Phase I Results
Fluoro — _— Pharma Fatty acid analog that detects regions of metabolic insufficiency PHASE | TRIAL COMPLETED 3 (15 NHV and 6 CAD patients) 4 = ai *+ CardioPET promising safety with no AES detected Infarcted region of the heart * Clinical findings consistent with MPI SPECT * Quality of CardioPET imag
Slide 21: The CardioPET Opportunity
The CardioPET Opp: Projected CardioPET Scans MiLLions umpt aa Est. 5! Year Revenue $605 millon 16 Est PET Est. FP sas Patients MarketSize Share 12 CCAD diagnosis »dasNeSS 3 Smilin L4millon 32% as Cardiac viability ardacvablty 4.6 millon OSmilion 80% 04 Myocardial a perfusion 12 millon 3.6milion 7.2%
Slide 22: VasoPET Indications and Clinical Use
VasoPET Indications and Clinical Use harma EVALUATION OF + Patients with acute cardiac event or stroke (risk of recurring event) + Therapy following acute cardiac eventor stroke (e.g., Plavix, lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE *+ Clinical symptoms; several imaging agents in
Slide 23: Detection of Inflamed Atherosclerotic Plaque
Fluoro . Detection Of Inflamed Atherosclerotic Plaque harma WHY INFLAMMATION IMAGING? af bas + Diagnosis before symptoms occur ; | + Crucial role at all stages of + atherosclerosis + May aid drug development DEVELOPMENT STATUS + Preclinical tes + IND preparation ongoing, + Plan to initiate Phase | p
Slide 24: The VasoPET Opportunity
The VasoPET Opportunity harma Est. 6 Year Revenue $408 million Est PET Mkt Market Patients ae Sereening for 59 milion 300,000 atherosclerosis Response to therapy (statins, 28millon 380,000 Follow-up after heartartack, —0-9milion $0,000 Follow-up after ti 08million 80,000 iLLions og o7 06 05 04 03 02
Slide 25: Targets Greatest Areas for Cost Reduction
Targets Greatest Areas for Cost Reduction harma Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomes-driven medicine offer greatest route to reducing the overall costs of healthcare M
Slide 26: Experienced Management Team and Advisors
Experienced Management Team and Advisors harma Thijs Spoor Presisent, CEO + Heatthcare executive wih >15 years medica industy experience + Former secutties analst at JP. Morgan and Credit Suisse coveting the medical device and biotechnology industries + Previous} ed the nuclear carcology portfoto an
Slide 27: Growth Strategy / Near-Term Milestones
Growth Strategy / Near-Term Milestones harma Capitalize on multiple cardiovascular molecular imaging agents for PET + Cardiac viability assessment + Myocardial perfusion imaging + Inflamed atherosclerotic plaque imaging, ‘Address unmet needs in cardiovascular diagnostics by providing + Diagnostic al
Slide 28: Slide 28
Slide 29: Multiple players in each value chain
ei iucr — _— Pharma Drug Development Distribution IBA Molecular Eckert Ziegler Cardinal He ‘Molecular Ins Covidien Siemen PETNET nner Development Multiple players in each value chain www. FluoroPharma.com
Slide 30: The cycle of classic medicine is reactive medical care
Fluoro The cycle of classic medicine is reactive medical care Reactive Medical Care Switch Drug Again. Switch Drug Select Drug Disease Severity Time Diagnose Disease: Treat Symptoms; Costly, Trial and Error Treatment www. FluoroPharma.com eaaralaea Wedlone Coalio, ANanars PeSEraNON
Slide 31: Shifting to outcomes focused personalized treatments increases efficiency
Shifting to outcomes focused personalized treatments increases efficiency arma. Efficient Medical Care Right Drug’ Disease Severity Diagno: Prognos! Diagnosis Health Management: Molecular Screening: Early Detection; Rapid Effective Treatment; Improved Quality of Care =e Fersnataea Wed Coalion Asanam
Slide 32: Cardiovascular Disease
Cardiovascular Disease harma of fe KER KEY FACTS - US AND WW WHO: “Neglected Global Epidemic + 16.7M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. + 1/3 of deaths in China, Yin Europe + 2.4M deaths US: top cause (38.5' tive Heart Failure (CHF) Malignant Arrhythmias (SCD) KEY
Slide 33: Outcomes partnerships drive clinical trial endpoints
Outcomes partnerships drive clinical trial endpoints Fluoro — ~ Pharma Economic pressures PAST FUTURE Fragmented + F& F&F FS SS S| mregaics, non-systems > systems of Whee Decisions by individual stakeholders in fare delivery (WAlgned (Conventional ‘Solo practitioners Quality patient care - anecdotal
Slide 34: Market Drivers for New PET Products
Market Drivers for New PET Products harma Growth in PET Low capacity Comprehensive adoption of early utilization diagnosis will improve utilization of technology 7 + Atcapacity, more patients could be Z 7 diagnosed earlier leading to better patient sais outcomes + Earlier diagnosis benefits the heal
Slide 35: Thank you for listening!
Fluo ae Phar Thank you for listening! i
FluoroPharma Medical — Investor Presentation (September 2012) on 6ix